AbbVie Inc. (NYSE:ABBV) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript January 31, 2025 AbbVie Inc. misses on earnings expectations. Reported EPS is $2.16 EPS, ...
Scientists Are Developing Brain Implants That Could Revolutionize Parkinson’s Treatment
Brain implants, made from small clusters of brain cells, could help restore neural pathways damaged by Parkinson’s disease.
Should we be worried about our drinking water?
Experts tell Sky News that although the UK's water treatment system is unable to get rid of tiny traces of "forever chemicals" that have been linked to cancers and other long-term health conditions, ...
AbbVie's newer immunology drugs are offsetting Humira's decline, sending stock up 4%
AbbVie Inc.'s stock rose 4% early Friday, after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs delivered growth needed to ...
I have a chronic, incurable disease. Here’s how I deal with it and keep on enjoying life.
Resisting the reality of chronic illness can lead to emotional distress. Acceptance, on the other hand, can open the door to proactive coping.
News Medical1d
Alzheimer’s and Parkinson’s linked to aging brain’s failing waste disposal
New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...
New York establishes statewide Parkinson's registry to advance research
New legislation signed into law by Governor Kathy Hochul is positioning New York as a leader in Parkinson’s Disease research. The new bill establ ...
Rolling Out1d
A breakthrough in Parkinson’s disease detection
AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...
Jupiter Neurosciences, Inc.: Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based ...
BioSpace2d
Inhibikase Scraps Parkinson’s Drug After Disappointing Mid-Stage Data
Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and ...
manilatimes2d
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale - MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity ...
FierceBiotech2d
Inhibikase hits pause on Parkinson's program over efficacy as it prioritizes lung drug
Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...